{"analyses":[{"ciLowerLimit":"4.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"379.18","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"20.86","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"1"}],"title":"Response"},{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"42"}],"title":"No response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \\>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.","groups":[{"description":"2x150mg film-coated tablets","id":"OG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"OG001","title":"Cohort A Investigators Choice of NHA"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable for response","reportingStatus":"POSTED","timeFrame":"Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).","title":"Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only","type":"SECONDARY","unitOfMeasure":"Participants"}